메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 12, 2025 -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR
- 김갑성 기자
- 2025-08-12 09:36
Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical trial sites actively recruiting now. MELBOURNE, Australia, Aug. 12, 2025 -- Avecho Biotechnology Limited (Avecho) is today alerting Australians to recruitment efforts for the largest ever clinical trial ('the Trial') for the treatment of insomnia with a pharmaceutical cannabidiol (CBD) product – with clinical trial sites now live across the country. The Trial is a placebo-controlled study assessing the use of CBD for insomnia, recruit
- 김갑성 기자
- 2025-08-12 08:32
Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global pre
- 김갑성 기자
- 2025-08-11 21:41
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children's Height Development

RICHMOND, VA., Aug. 11, 2025 -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy. AGEBOX, a trailblazer in pediatric health, is responding to the growing parental demand for safe, hormone-free height support—with iKids-Growth, the first-ever supple
- 김갑성 기자
- 2025-08-11 21:30
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences industry, proudly announces the start of its 25th year of operations. With over two decades of expertise, Caliber has helped pharmaceutical and biotechnology companies in 17 countries enhance quality systems, streamline operations, and ensure regulatory compliance. To mark this milestone, Caliber unveiled a new anniversary logo, officially installed at the company's India headquarters in Hyderabad. "The logo brings together th
- 김갑성 기자
- 2025-08-11 21:22
EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS

PLANTATION, Fla., Aug. 11, 2025 -- Everise, a global leader in transforming customer experiences, today announced two senior leadership appointments as the company continues its growth trajectory and expansion in global markets. Industry veteran Robert Jimenez joins as Chief Revenue Officer (CRO), while accomplished finance leader Steven Amaya takes on the role of Chief Financial Officer (CFO). These strategic appointments come as Everise continues to expand its global footprint, scale its operations, and deepen its partnerships with some of the world's leading
- 김갑성 기자
- 2025-08-11 21:00
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK

Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conference in Palos Verdes CA last week. Dr. Kennedy previewed highlights from his team's use of advanced AI driven statistics to analyze the data from a large longevity study of 4,260 health enthusiast subjects who purchased at least one saliva based DNA epigenetic test between 2020 and 2025. The subjects de
- 김갑성 기자
- 2025-08-11 20:06
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs

— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling— Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies— AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fa
- 김갑성 기자
- 2025-08-11 20:00
"Senior Speed Stack" Introduces Emerging Sport Stacking to Help Reduce Cognitive Decline in the Elderly

Key Points: The Junior Chamber International (JCI) North District organized the "2025 Senior Speed Stack Closing Ceremony," introducing sport stacking to help delay cognitive decline in the elderly. Celebrity Tiffany Lau (Tiffany) participated in speed stacking activities with seniors. Assistant Professor of Teaching Senior Dr Mok Kam-Ming from Lingnan University's School of Interdisciplinary Studies, conducted a tracking study as part of the project, finding that seniors who consistently participated in speed stacking training showed a downward trend in stress and anxi
- 김갑성 기자
- 2025-08-11 19:17
Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2025, and provide a business update on August 29, 2025. The Company will hold live conference calls in English and Mandarin on August 29, 2025, Beijing Time. The English session of the conference call will be held at 8:00 AM on August 29, 2025, Beijing
- 김갑성 기자
- 2025-08-11 17:11

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 40분